Patents by Inventor Roberto Porta
Roberto Porta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9782429Abstract: The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.Type: GrantFiled: July 3, 2014Date of Patent: October 10, 2017Assignee: GENTIUM S.R.L.Inventors: Laura Ferro, Roberto Porta, Massimo Iacobelli, Alessandro Massimo Gianni, Carmelo Carlo Stella
-
Publication number: 20140363394Abstract: The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.Type: ApplicationFiled: July 3, 2014Publication date: December 11, 2014Inventors: Laura FERRO, Roberto PORTA, Massimo IACOBELLI, Alessandro Massimo GIANNI, Carmelo Carlo STELLA
-
Patent number: 8771663Abstract: The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.Type: GrantFiled: April 6, 2010Date of Patent: July 8, 2014Assignee: Gentium SPAInventors: Laura Ferro, Roberto Porta, Massimo Iacobelli, Massimo Alessandro Gianni, Carmelo Carlo Stella
-
Patent number: 7838506Abstract: The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing.Type: GrantFiled: January 17, 2008Date of Patent: November 23, 2010Assignee: Gentium SpAInventors: Manlio Palumbo, Barbara Gatto, Rodolfo Pescador, Roberto Porta, Laura Iris Ferro
-
Publication number: 20100254938Abstract: The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterised in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilise haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.Type: ApplicationFiled: April 6, 2010Publication date: October 7, 2010Applicant: Gentium SPAInventors: Laura Ferro, Roberto Porta, Massimo Iacobelli, Massimo Alessandro Gianni, Carmelo Carlo Stella
-
Publication number: 20080176814Abstract: The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing.Type: ApplicationFiled: January 17, 2008Publication date: July 24, 2008Applicant: GENTIUM SPAInventors: Manlio PALUMBO, Barbara GATTO, Rodolfo PESCADOR, Roberto PORTA, Laura Iris FERRO
-
Patent number: 7338777Abstract: Method for determining the biological activity of defibrotide by a) bringing into contact defibrotide, plasmin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide.Type: GrantFiled: June 17, 2004Date of Patent: March 4, 2008Assignee: Gentium SPAInventors: Roberto Porta, Franco Cattaneo, Laura Ferro
-
Publication number: 20060148745Abstract: The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing.Type: ApplicationFiled: September 27, 2005Publication date: July 6, 2006Inventors: Manlio Palumbo, Barbara Gatto, Rodolfo Pescador, Roberto Porta, Laura Ferro
-
Publication number: 20050009131Abstract: An enzymatic method for determining the biological activity of defibrotide is described. This method, which is based on the capacity of defibrotide to potentiate the enzymatic activity of plasmin, comprises the steps of: a) bringing into contact defibrotide, plasmin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product and b) measuring the amount of product formed at successive times.Type: ApplicationFiled: June 17, 2004Publication date: January 13, 2005Applicant: Gentium SPAInventors: Roberto Porta, Franco Cattaneo, Laura Ferro
-
Patent number: 6767554Abstract: The invention relates to the use as medicaments, specifically as antiinflammatories, of complexes formed by cationic liposomes and polydeoxyribonucleotides having a molecular weight in the range 7,000-60,000 Da obtainable by depolymerization of nucleic acids, wherein in said complexes the polydeoxyribonucletoides are located on the outer surface of the liposome.Type: GrantFiled: June 11, 1999Date of Patent: July 27, 2004Assignee: Gentum S.p.A.Inventors: Roberto Porta, Laura Ferro, Fabio Trento, Claudio Nastruzzi, Elisabetta Esposito, Enea Menegatti
-
Publication number: 20040131588Abstract: A description is given of a method of increasing the amount of stem cells and progenitor cells in the peripheral blood of a mammal: the method is characterised by the administration of defibrotide in combination or in temporal proximity with at least one haematopoietic factor, (preferably G-CSF) having the capacity to mobilise haematopoietic progenitors.Type: ApplicationFiled: December 29, 2003Publication date: July 8, 2004Inventors: Laura Ferro, Roberto Porta, Massimo Lacobelli, Massimo Alessandro Gianni, Carmelo Carlo Stella
-
Publication number: 20020142029Abstract: The invention relates to the use as medicaments, specifically as antiinflammatories, of complexes formed by cationic liposomes and polydeoxyribonucleotides having a molecular weight in the range 7,000-60,000 Da obtainable by depolymerization of nucleic acids, wherein in said complexes the polydeoxyribonucletoides are located on the outer surface of the liposome.Type: ApplicationFiled: June 11, 1999Publication date: October 3, 2002Inventors: ROBERTO PORTA, LAURA FERRO, FABIO TRENTO, CLAUDIO NASTRUZZI, ELISABETTA ESPOSITO, ENEA MENEGATTI
-
Patent number: 6232302Abstract: Compositions containing depolymerized fucane sulphates characterized by the following parameters (percentages by weight on the dry product): Molecular weight: 5,000-30,000 dalton; Sulphur: 5-16%; Fucose: 25-60%; Uronic acids 2-25%; they increase the percentage of growing hair and inhibit the Pytirosporun growth on the skin.Type: GrantFiled: June 16, 1999Date of Patent: May 15, 2001Assignee: Crinos Industria Farmacobiologica S.p.A.Inventors: Pia Alberico, Armando Cedro, Danilo Moltrasio, Roberto Porta
-
Patent number: 5948405Abstract: Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity.Fucan sulfates having molecular weight between 14000 and 29000 Dalton show a remarkable anticoagulant activity both in the global coagulation mechanism (APTT) and in the last phase of coagulation (antithrombinic activity). These compounds are useful also as antithrombotic drugs.Type: GrantFiled: December 18, 1997Date of Patent: September 7, 1999Assignee: Crinos Industria Farmacobiologica S.p.A.Inventors: Armando Cedro, Roberto Porta, Franco Cattaneo, Fabio Trento, Laura Ferro, Ennio Lanzarotti
-
Patent number: 5646127Abstract: There are provided oligodeoxyribonucleotides of animal origin, having a molecular weight between 4000 and 10000 daltons, that can be obtained by fractionation of polydeoxyribonucleotides or otherwise by chemical or enzymatic depolymerization of high molecular weight deoxyribonucleic acids. The compounds are endowed with a significant anti-ischemic activity.Type: GrantFiled: August 3, 1995Date of Patent: July 8, 1997Assignee: Crinos Industria Farmacobiologica S.p.A.Inventors: Ennio Lanzarotti, Marisa Mantovani, Giuseppe Prino, Roberto Porta, Cedro Armando, Danilo Moltrasio
-
Patent number: 5646268Abstract: The invention discloses new oligodeoxyribonucleotides of animal origin, having a molecular weight comprised between 4000 and 10000 daltons, that can be obtained by fractionation of polydeoxyribonucleotides or otherwise by chemical or enzymatic depolymerization of high molecular weight deoxyribonucleic acids. The new compounds are endowed with a significant anti-ischemic activity.Type: GrantFiled: January 31, 1996Date of Patent: July 8, 1997Assignee: Crinos Industria Farmacobiologica S.p.A.Inventors: Ennio Lanzarotti, Marisa Mantovani, Giuseppe Prino, Roberto Porta, Armando Cedro, Danilo Moltrasio
-
Patent number: 5116617Abstract: Pharmaecutical composition for topical use containing Defibrotide have been found effective in the therapy of local pathologies characterized by a reduced resistance of the blood capillary vessels.Type: GrantFiled: August 16, 1990Date of Patent: May 26, 1992Assignee: Crinos Industria Farmacobiologica S.p.A.Inventors: Marisa Mantovani, Roberto Porta, Giuseppe Prino
-
Patent number: 5008253Abstract: Novel derivatives are disclosed as obtained from chondroitin sulfate, dermatan sulfate and hyaluronic acid, having a molar ratio between sulfate groups and carboxylic groups like that of heparin and furthermore characterized by possessing, as the heparin, the sulfoamino group at the carbon atom at the 6 position of hexosamine.The novel compounds show a very remarkable clearing activity in comparison with the starting mucopolysaccharides, this activity being similar and for some derivatives comparable with that of heparin.Moreover, differently from what normally happens upon sulfating the sulfomucopolysaccharides, the anticoagulating activity of the novel compounds is negligible or anyhow very reduced.The compounds of the present invention find use in the therapy of arteriosclerosis.Type: GrantFiled: May 2, 1989Date of Patent: April 16, 1991Assignee: Crinos Industria Farmacobiologica S.p.A.Inventors: Benito Casu, Giangiacomo Torri, Annamaria Naggi, Marisa Mantovani, Rodolfo Pescador, Roberto Porta, Giuseppe Prino
-
Patent number: 4235904Abstract: The invention provides novel 4-aryl-5-aminoalkyl-1,3-dioxol-2-ones having hypocholesterolemic, hypolipemic, antiulcer, antihistaminic and antiserotoninic activities.Type: GrantFiled: March 1, 1979Date of Patent: November 25, 1980Assignee: Instituto Luso Farmaco d'Italia S.p.A.Inventors: Elso Manghisi, Giuseppe Cascio, Giancarlo Fregnan, Roberto Porta